This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.
|Number of pages||10|
|Journal||Cytometry Part B-clinical Cytometry|
|Early online date||13 Dec 2021|
|Publication status||Published - Jan 2023|
- flow cytometry
- myelodysplastic syndromes
- PROGNOSTIC SCORING SYSTEM